ATE237353T1 - Antikörper gegen p-selectin und ihre verwendung - Google Patents

Antikörper gegen p-selectin und ihre verwendung

Info

Publication number
ATE237353T1
ATE237353T1 AT93911098T AT93911098T ATE237353T1 AT E237353 T1 ATE237353 T1 AT E237353T1 AT 93911098 T AT93911098 T AT 93911098T AT 93911098 T AT93911098 T AT 93911098T AT E237353 T1 ATE237353 T1 AT E237353T1
Authority
AT
Austria
Prior art keywords
selectin
antibodies
compositions
measured
cell line
Prior art date
Application number
AT93911098T
Other languages
English (en)
Inventor
Robert W Chestnut
Margaret J Polley
James C Paulson
Robert Bayer
Original Assignee
Aeres Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeres Biomedical Ltd filed Critical Aeres Biomedical Ltd
Application granted granted Critical
Publication of ATE237353T1 publication Critical patent/ATE237353T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93911098T 1992-05-05 1993-05-04 Antikörper gegen p-selectin und ihre verwendung ATE237353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88019692A 1992-05-05 1992-05-05
PCT/US1993/004274 WO1993021956A1 (en) 1992-05-05 1993-05-04 Antibodies to p-selectin and their uses

Publications (1)

Publication Number Publication Date
ATE237353T1 true ATE237353T1 (de) 2003-05-15

Family

ID=25375701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911098T ATE237353T1 (de) 1992-05-05 1993-05-04 Antikörper gegen p-selectin und ihre verwendung

Country Status (11)

Country Link
EP (1) EP0642356B1 (de)
JP (2) JP3720352B2 (de)
AT (1) ATE237353T1 (de)
AU (1) AU681850B2 (de)
CA (1) CA2135083C (de)
DE (1) DE69332881T2 (de)
DK (1) DK0642356T3 (de)
ES (1) ES2197150T3 (de)
IL (1) IL105614A (de)
NZ (2) NZ252542A (de)
WO (1) WO1993021956A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI955261A7 (fi) * 1993-05-04 1996-01-03 Cytel Corp P-selektiinin vasta-aineita ja niiden käyttö
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
JPH0940582A (ja) * 1995-07-28 1997-02-10 Sumitomo Pharmaceut Co Ltd 神経障害治療剤
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
HUE041957T2 (hu) * 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
BRPI0918419A2 (pt) 2008-09-19 2015-11-24 Hoffmann La Roche nova formulação anticorpo
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3595645A1 (de) 2017-03-15 2020-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmazeutische zusammensetzungen zur behandlung von thrombosen bei patienten mit einem myeloproliferativem neoplasma
ES2911600T3 (es) 2017-06-20 2022-05-20 Inst Nat Sante Rech Med Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
EP3762424A1 (de) 2018-03-08 2021-01-13 Novartis AG Verwendung eines anti-p-selectin-antikörpers
CA3142011A1 (en) 2019-06-07 2020-12-10 Novartis Ag Use of an anti-p-selectin antibody
AU2020326490A1 (en) 2019-08-08 2022-03-24 Novartis Ag Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
DK0496832T3 (da) * 1989-10-20 1996-12-30 New England Medical Center Inc Inhibering af PADGEM-formidlet cellebinding
ATE224911T1 (de) * 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
AU1128195A (en) * 1993-10-26 1995-05-22 Mayo Foundation For Medical Education And Research Direct fluorescence-conjugated immunoassay for platelet activation
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein

Also Published As

Publication number Publication date
JP2006045234A (ja) 2006-02-16
JP3720352B2 (ja) 2005-11-24
NZ286804A (en) 2000-08-25
EP0642356B1 (de) 2003-04-16
WO1993021956A1 (en) 1993-11-11
NZ252542A (en) 1997-08-22
DE69332881D1 (de) 2003-05-22
EP0642356A4 (de) 1998-05-27
CA2135083A1 (en) 1993-11-11
IL105614A0 (en) 1993-09-22
DK0642356T3 (da) 2003-08-04
EP0642356A1 (de) 1995-03-15
CA2135083C (en) 2004-01-06
ES2197150T3 (es) 2004-01-01
IL105614A (en) 1999-06-20
AU681850B2 (en) 1997-09-11
JPH08503360A (ja) 1996-04-16
AU4236093A (en) 1993-11-29
DE69332881T2 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
DE69332881D1 (de) Antikörper gegen p-selectin und ihre verwendung
DK1053239T3 (da) Gluccocorticoid-selektive, anti-inflammatoriske midler
CA2047717A1 (en) Monoclonal antibodies for small moieties, methods therefor
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
DK1053240T3 (da) Glucocorticoid-selektiv antiinflammatoriske midler
EE200100355A (et) Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ATE195528T1 (de) Steroidnitritesterderivate und ihre verwendung als entzündungshemmende medikamente
IT1283890B1 (it) Additivo per il miglioramento della pompabilita' di composizioni cementizie
DE69416403D1 (de) Calanolide und aehnliche verbindungen diese enthaltende zusammensetzungen und ihre verwendung
NO944933D0 (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
BR9611472A (pt) Compostos de di-terc-butilfenol contendo enxofre úteis como agentes antiinflamatórios
EP0681611A4 (de) In der anaerobischen bestimmung von analyten verwendbare zusammensetzungen.
CA2170606A1 (en) Type i angiotensin ii receptor specific monoclonal antibodies and hybridomas
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita
EA200000365A1 (ru) Полиморфные модификации дофетилида
FI913128A7 (fi) Koostumus keskitisleiden kylmävirtausominaisuuksien parantamiseksi
DK463885D0 (da) Indomethacin- eller oxicam-baseret anti-inflammatorisk praeparat
KR930703420A (ko) 유출 연료의 저온성을 개선시키기 위한 다관능가 첨가제 및 그를 함유하는 조성물
IT8048496A0 (it) Perfici di acciaio senza la emissio procedimento di metallizzazione in ne di fanghi di scarico particolare galvanizzazione di su
BR9407232A (pt) Compostos de tiocarbamoíla
FI853957A7 (fi) Koostumukset erityisesti vulkanisaattien ominaisuuksien parantamiseksi sekä luonnollisten ja synteettisten kumien vahvistamiseksi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0642356

Country of ref document: EP

REN Ceased due to non-payment of the annual fee